Thomas J. Herzfeld Advisors’s AbbVie ABBV Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12	Closed	-$2.06K	–	157
2024 Q2	$2.06K	Buy	+12	New	+$1.99K	﹤0.01%	212
2023 Q4	–	Sell	-722	Closed	-$108K	–	157
2023 Q3	$108K	Hold	722	–	–	0.04%	104
2023 Q2	$97.3K	Buy	722 +15	+2%	+$2.2K	0.04%	100
2023 Q1	$113K	Hold	707	–	–	0.05%	86
2022 Q4	$114K	Buy	707 +3	+0.4%	+$460	0.05%	88
2022 Q3	$94K	Hold	704	–	–	0.04%	91
2022 Q2	$108K	Hold	704	–	–	0.04%	96
2022 Q1	$114K	Buy	704 +5	+0.7%	+$726	0.04%	102
2021 Q4	$95K	Hold	699	–	–	0.03%	123
2021 Q3	$75K	Hold	699	–	–	0.03%	118
2021 Q2	$79K	Hold	699	–	–	0.03%	125
2021 Q1	$76K	Buy	699 +600	+606%	+$64.2K	0.03%	133
2020 Q4	$11K	Buy	99 +12	+14%	+$1.15K	0.01%	196
2020 Q3	$7K	Buy	87 +12	+16%	+$1.13K	﹤0.01%	168
2020 Q2	$7K	Buy	+75	New	+$6.6K	﹤0.01%	204

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Thomas J. Herzfeld Advisors's ABBV Position: Q3 2024 in Review

Thomas J. Herzfeld Advisors sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 12 shares — an estimated $2.06K sold.

Thomas J. Herzfeld Advisors first reported a position in ABBV in Q2 2020 and held it in 15 quarters. The position peaked at $114K in Q4 2022. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Thomas J. Herzfeld Advisors reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
Thomas J. Herzfeld Advisors sold 12 AbbVie shares in Q3 2024, an estimated $2.06K.
Thomas J. Herzfeld Advisors first reported a position in AbbVie in Q2 2020 and held it in 15 quarters.
Thomas J. Herzfeld Advisors's AbbVie position peaked at $114K in Q4 2022.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.